Flush with cash, Intellikine pioneers PI3 kinase chemistry

La Jolla, CA-based startup Intellikine has quickly racked up 1,500 drug candidates that can influence the PI3 kinase pathway, an indication of the biotech company's intensity and a key reason it has been able to attract considerable support from the venture capital community.

Xconomy's Luke Timmerman profiles the company and its CEO, Troy Wilson, who has collected $28 million in a venture round that could total $51 million.

"We may not be first in class, but we want to be best in class," Wilson tells the tech news site. "We wanted to look at every possible kind of inhibitor."

- read the profile from Xconomy

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.